Get the Stockscreener App
4.53
5.62%
-0.27
After Hours:
4.62
0.09
+1.99%
Cervomed Inc stock is traded at $4.53, with a volume of 91,510.
It is down -5.62% in the last 24 hours and down -40.32% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$4.80
Open:
$4.8
24h Volume:
91,510
Relative Volume:
1.24
Market Cap:
$41.91M
Revenue:
$6.16M
Net Income/Loss:
$-25.59M
P/E Ratio:
-1.5646
EPS:
-2.8954
Net Cash Flow:
$-24.93M
1W Performance:
-1.52%
1M Performance:
-40.32%
6M Performance:
-51.81%
1Y Performance:
+107.80%
1-Day Range:
$4.40
$4.80
1-Week Range:
$4.40
$5.65
52-Week Range:
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
4.53 | 44.41M | 6.16M | -25.59M | -24.93M | -2.8954 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Aug Fed Impact: What is CervoMed Incs revenue forecastJuly 2025 Fed Impact & Safe Capital Growth Stock Tips - baoquankhu1.vn
Winners Losers: Is ALCY affected by consumer sentiment2025 Macro Impact & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Market Outlook: Is CervoMed Inc currently under institutional pressure2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn
Nasdaq Moves: Whats ACRES Commercial Realty Corps historical returnJuly 2025 Patterns & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Inc targets breakthrough in Lewy body dementia treatment - Traders Union
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Is CervoMed Inc stock good for income investorsWeekly Trade Summary & Daily Stock Trend Reports - baoquankhu1.vn
Geopolitics Watch: Is CervoMed Inc stock a good pick for beginnersTrade Volume Report & Verified Chart Pattern Signals - baoquankhu1.vn
Market Overview: Does Coupang Inc have pricing powerChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
CervoMed (NASDAQ:CRVO) Upgraded at Zacks Research - Defense World
Growth Review: Can VSTEW sustain its profitabilityTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Ideas Watch: Is CervoMed Inc DP8 stock overpriced at current multiplesTrade Analysis Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Will CervoMed Inc. stock see insider buying2025 Breakouts & Breakdowns & Smart Swing Trading Techniques - Улправда
Will CervoMed Inc. stock deliver consistent dividends2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Is CervoMed Inc. (DP8) stock overpriced at current multiples2025 Year in Review & Daily Market Momentum Tracking - Улправда
CervoMed Releases Updated Investor Presentation and Business Overview - TipRanks
Is CervoMed Inc. stock a dividend growth opportunityWeekly Trade Review & Long-Term Growth Stock Strategies - Улправда
Will CervoMed Inc. stock gain from strong economyGlobal Markets & High Win Rate Trade Tips - Улправда
Aug Weekly: Is CervoMed Inc stock vulnerable to regulatory risksTrade Analysis Summary & Growth Focused Stock Pick Reports - Bộ Nội Vụ
Is CervoMed Inc DP8 a good long term investmentMarket Sentiment Report & Learn From the Strategies of Institutions - earlytimes.in
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Can CervoMed Inc. stock rebound after recent weakness2025 Market Overview & Risk Controlled Swing Alerts - Улправда
Will CervoMed Inc. (DP8) stock return to pre crash levels2025 Trading Volume Trends & Technical Pattern Based Signals - Улправда
What analyst consensus says on CervoMed Inc. stockStock Surge & Verified High Yield Trade Plans - Улправда
Is CervoMed Inc. stock vulnerable to regulatory risksEarnings Miss & Technical Analysis for Trade Confirmation - DonanımHaber
Aug Patterns: Will CervoMed Inc. stock gain from strong economyProduct Launch & AI Based Buy and Sell Signals - DonanımHaber
Why CervoMed Inc. (DP8) stock attracts wealthy investorsStop Loss & Advanced Technical Signal Analysis - DonanımHaber
CervoMed (NASDAQ:CRVO) Receives Buy Rating from HC Wainwright - Defense World
Can CervoMed Inc. stock sustain institutional interest2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Cantor Fitzgerald initiates CervoMed stock with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus
HC Wainwright Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - MarketBeat
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com India
CervoMed Earnings Notes - Trefis
CEO Change: Is CervoMed Inc DP8 stock supported by strong fundamentals2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - moha.gov.vn
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):